<DOC>
	<DOCNO>NCT01143987</DOCNO>
	<brief_summary>Active parathyroid gland among renal dialysis patient contribute calcify hardened blood vessel . Such damage blood vessel , turn , take significant toll term cardiovascular disease . Calcimimetics suggest low risk vascular calcification . Role cinacalcet demonstrate animal model human data lacking . The investigator design open label pilot study evaluate effect cinacalcet 20 peritoneal dialysis patient inadequately control secondary hyperparathyroidism despite standard treatment . The primary outcome aortic pulse wave velocity 26 52 month cinacalcet treatment .</brief_summary>
	<brief_title>Cincalcet Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism</brief_title>
	<detailed_description>Mineral metabolism disturbance hyperparathyroidism contribute arterial stiffness vascular calcification . The vascular damage , turn , contribute significant cardiovascular morbidity mortality end-stage renal disease patient . Calcimimetics suggest low risk vascular calcification . Role cinacalcet demonstrate animal model human data lack . We design open label pilot study evaluate effect cinacalcet 20 peritoneal dialysis patient inadequately control secondary hyperparathyroidism despite standard treatment . The primary outcome aortic pulse wave velocity 26 52 month cinacalcet treatment .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>plasma parathyroid hormone level least 300 pg/ml ( 31.8 pmol/L ) age 18 old peritoneal dialysis least three month willingness give write consent comply study protocol evidence cancer , active infection disease limited life expectancy diseases know cause hypercalcaemia adjust serum calcium level 2.1 mmol/L ( 8.4 mg/dL ) correction albumin participation another interventional study within last 30 day randomization history psychological illness condition would interfere patient 's ability understand requirement study and/or comply study procedures patient receive drug narrow therapeutic index metabolize cytochrome P450 2D6 ( inhibit cinacalcet ) : flecainide , thioridazine tricyclic antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>hyperparathyroidism</keyword>
	<keyword>pulse wave velocity</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>arterial stiffness</keyword>
</DOC>